Home »
A therapeutic antibody developed by scientists at UCL has been shown to unblock and normalize blood vessels inside cancerous tumors, enabling the more effective delivery of targeted cancer treatments. The findings in mice, published in the journal Med, are the first to demonstrate that inhibiting the activity of LRG1, a protein produced in many tumorous tissues, liberates disorganized angiogenesis (blood […]
Read more
LONDON — Pharmaceutical company Merck agreed to allow other drug makers to produce its COVID-19 pill, in a move aimed at helping millions of people in poorer countries get access to the potentially life-saving drug, a United Nations-backed public health organization said on Wednesday. The Medicines Patent Pool said in a statement that it had signed a voluntary licensing agreement […]
Read more
A non-toxic, bacteria-based system developed at the University of Massachusetts Amherst can detect when it is inside a cancer cell and then release its payload of therapeutic drugs directly into the cell. The work, published in Nature Communications today, could lead to effective, targeted therapies for currently untreatable cancers, such as liver or metastatic breast cancer. The inability to penetrate […]
Read more
A common treatment for Alzheimer’s disease may help people with the earliest stages of the disease maintain mitochondrial function in their muscles in addition to slowing cognitive decline. The first-of-its-kind study is published ahead of print in Function. Research suggests people with Alzheimer’s disease, a form of cognitive impairment, have mitochondrial dysfunction throughout the body. Mitochondria, often described as the […]
Read more
University of Utah Health scientists have identified a molecule that slows cells’ production of alpha-synuclein, a protein that forms toxic aggregates in the brains of people with Parkinson’s disease. Its discovery points toward a new strategy for treating the disease and potentially stopping its progression. Researchers led by Associate Professor of Neurology Daniel Scoles, Ph.D., reported on the molecule, known […]
Read more
Epilepsy comes in a variety of forms. Those affected by a genetically determined variety have severe epileptic seizures as early as the first year of life. The disease is accompanied by severe developmental disorders: it is difficult for them to walk, they have difficulty concentrating and later have problems with speech, spelling and calculations. Until now, this form of epilepsy […]
Read more
A new study from Linköping University has shown that the tumor-inhibiting gene TET2 is silenced in a large fraction of cases of acute lymphoblastic leukemia (ALL) in children. The scientists show that the gene can be reactivated by treatment with an existing drug, 5-azacytidine. The results, published in the scientific journal PNAS, suggest that 5-azacytidine may function as targeted therapy […]
Read more
A repurposed drug that was first used against COVID-19 in the United States by Emory researchers is emerging as a major option for treatment of hospitalized patients needing respiratory support. The anti-inflammatory drug baricitinib was originally developed for rheumatoid arthritis by Eli Lilly and Company and Incyte. It has now been tested in several clinical trials in people with severe […]
Read more
Remdesivir is an antiviral drug originally discovered as part of a program to develop antiviral agents with activity against novel emerging viruses. In the first months of the COVID-19 pandemic, it was tested as a potential therapeutic and found to measurably reduce recovery time for hospitalized COVID-19 patients. The Food and Drug Administration approved its use in October 2020 and […]
Read more
WASHINGTON — When a controversial Alzheimer’s drug won U.S. approval, surprise over the decision quickly turned to shock at how long it might take to find out if it really works — nine years. Drugmaker Biogen has until 2030 to complete a study confirming whether its new drug Aduhelm truly slows the brain-destroying disease. That’s under the terms of the […]
Read more